Erythema News and Research

RSS

Burt's Bees presents new research supporting the power of natural skin care at AAD VMX 2020

Burt's Bees, a leader in science-backed natural skin care, today announced new research supporting the proven power of nature-based solutions that deliver the tolerability and efficacy that are critical for dermatologists and their patients.

12 Jun 2020

Challenges of diagnosing Lyme disease in the absence of classic symptoms

Lyme disease can have unusual presentations. Physicians and the public should be aware of its different manifestations, as people spend more time outside in the warmer weather and as the areas in Canada where the black legged tick is found expand.

26 May 2020

A first-in-human trial with promising MERS coronavirus vaccine

Over the past 20 years, coronaviruses have been responsible for large outbreaks, resulting in severe respiratory illness and a number of deaths.

22 Apr 2020

Study identifies two new viruses in Brazilian patients with suspected dengue

Two new species of viruses have been identified in blood samples taken from patients in Brazil's northern region who had similar symptoms to those of dengue or Zika, such as high fever, severe headache, rash and red skin spots.

17 Apr 2020

A retrospective review of 5,000 non-surgical rhinoplasties performed to date

As patients continue to seek non-invasive treatments across the cosmetic spectrum, "liquid rhinoplasty" is emerging as the non-surgical alternative to the traditional nose job.

27 Feb 2020

Braincool completes patient recruitment to study Cooral System for prevention of Oral Mucositis

BrainCool AB, a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, is pleased to announce that it has completed patient recruitment in the Scandinavian multi-center pivotal trial of 180 patients to investigate the patented Cooral® System for prevention of Oral Mucositis, one of the most debilitating side-effects of both standard and high-dose chemotherapeutic oncology treatments.

11 Feb 2020

Research highlights benefits of oral prednisolone in patients with hand osteoarthritis

Research presented at the 2019 ACR/ARP Annual Meeting found that a six-week treatment with low-dose oral prednisolone substantially improves pain and decreases signs of inflammation in patients with painful hand osteoarthritis.

11 Nov 2019

Lyme vaccine on the horizon, says new study

Lyme disease is a dreaded disease caused by the bite of an infected tick. The only way to prevent it is by not getting bitten by the tick. However, this is not a practical recommendation, since even today about 300,000 thousand people are diagnosed with this infection, in the US alone, and over 100,000 in Europe, each year.

17 Oct 2019

Early detection method for pinpointing molecular signatures of Lyme disease

When researchers examined the mitochondrial DNA of Ötzi, a man entombed in ice high in the Tyrolean Alps some 5,300 years ago, they made a startling discovery.

26 Aug 2019

FDA clears existing tests with new indications to aid in the diagnosis of Lyme disease

Today, the U.S. Food and Drug Administration cleared for marketing four previously cleared tests with new indications to aid in the diagnosis of Lyme disease.

30 Jul 2019

Sequencing data could be used to prevent lyme disease

Researchers have successfully sequenced the genome of the animal that could carry the bacteria causing Lyme disease.

25 Jul 2019

Wear protective clothing to reduce the risk of skin damage from sun's UV rays

Whenever you're outdoors this summer, be sure to take steps to prevent solar erythema, the acute cutaneous reaction to excessive exposure to ultraviolet (UV) radiation.

25 Jun 2019

Quidel receives CE mark to use Sofia 2 Lyme+ Fluorescent Immunoassay with Sofia 2 analyzer

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received CE Mark to market Quidel's Sofia 2 Lyme+ FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii from serum and plasma specimens.

19 Dec 2018

Blocking activity of plasma protein can be possible way to protect against radiation-induced injury

It is possible to prevent certain injuries that can occur in radiation therapy against cancer. By blocking the activity of a plasma protein during and immediately after radiation, the patient can be protected against injury. This is shown in a new doctoral thesis at Umeå University, Sweden.

20 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Leadiant Biosciences announces FDA approval of Revcovi for treating pediatric, adult ADA-SCID patients

Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.

7 Oct 2018

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence.

7 Sep 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

Lyme disease researcher dispels misconceptions about ticks and provides prevention tips

Lyme disease is now the most reported vector-borne disease in the United States and the CDC released a report showing that diseases from biting insects, ticks, and mosquitos in the U.S. have tripled since 2004.

25 May 2018

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).

28 Apr 2018